Form 8-K - Current report:
SEC Accession No. 0000950170-24-059749
Filing Date
2024-05-14
Accepted
2024-05-14 17:00:20
Documents
12
Period of Report
2024-05-14
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K ubx-20240514.htm   iXBRL 8-K 41893
2 EX-99.1 ubx-ex99_1.htm EX-99.1 132639
  Complete submission text file 0000950170-24-059749.txt   300463

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ubx-20240514.xsd EX-101.SCH 28784
15 EXTRACTED XBRL INSTANCE DOCUMENT ubx-20240514_htm.xml XML 4538
Mailing Address 285 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 285 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 416-1192
Unity Biotechnology, Inc. (Filer) CIK: 0001463361 (see all company filings)

EIN.: 264726035 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38470 | Film No.: 24945476
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)